These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 19847912)

  • 1. Dopamine D2 receptor knockout mice develop features of Parkinson disease.
    Tinsley RB; Bye CR; Parish CL; Tziotis-Vais A; George S; Culvenor JG; Li QX; Masters CL; Finkelstein DI; Horne MK
    Ann Neurol; 2009 Oct; 66(4):472-84. PubMed ID: 19847912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation.
    Bellucci A; Collo G; Sarnico I; Battistin L; Missale C; Spano P
    J Neurochem; 2008 Jul; 106(2):560-77. PubMed ID: 18410503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
    Inden M; Kitamura Y; Tamaki A; Yanagida T; Shibaike T; Yamamoto A; Takata K; Yasui H; Taira T; Ariga H; Taniguchi T
    Neurochem Int; 2009 Dec; 55(8):760-7. PubMed ID: 19647776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine receptor agonists reverse behavioral abnormalities of alpha-synuclein transgenic mouse, a new model of Parkinson's disease.
    Wakamatsu M; Iwata S; Funakoshi T; Yoshimoto M
    J Neurosci Res; 2008 Feb; 86(3):640-6. PubMed ID: 17896793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra.
    Galvin JE
    Acta Neuropathol; 2006 Aug; 112(2):115-26. PubMed ID: 16791599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
    Alvarez-Fischer D; Henze C; Strenzke C; Westrich J; Ferger B; Höglinger GU; Oertel WH; Hartmann A
    Exp Neurol; 2008 Mar; 210(1):182-93. PubMed ID: 18053987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The nigro-striatal and nigro-amygdaloid pathways undergo different degeneration processes in brains of dementia with Lewy bodies.
    Iseki E; Marui W; Yamamoto R; Togo T; Katsuse O; Kato M; Iwatsubo T; Kosaka K; Arai H
    Neurosci Lett; 2005 May 20-27; 380(1-2):161-5. PubMed ID: 15854770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wild-type and mutant alpha-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD.
    Miller RM; Kiser GL; Kaysser-Kranich T; Casaceli C; Colla E; Lee MK; Palaniappan C; Federoff HJ
    Exp Neurol; 2007 Mar; 204(1):421-32. PubMed ID: 17254569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice.
    Wakamatsu M; Ishii A; Iwata S; Sakagami J; Ukai Y; Ono M; Kanbe D; Muramatsu S; Kobayashi K; Iwatsubo T; Yoshimoto M
    Neurobiol Aging; 2008 Apr; 29(4):574-85. PubMed ID: 17174013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nigral burden of alpha-synuclein correlates with striatal dopamine deficit.
    Kovacs GG; Milenkovic IJ; Preusser M; Budka H
    Mov Disord; 2008 Aug; 23(11):1608-12. PubMed ID: 18649394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression.
    Maingay M; Romero-Ramos M; Carta M; Kirik D
    Neurobiol Dis; 2006 Sep; 23(3):522-32. PubMed ID: 16806952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice.
    Fornai F; Lenzi P; Ferrucci M; Lazzeri G; di Poggio AB; Natale G; Busceti CL; Biagioni F; Giusiani M; Ruggieri S; Paparelli A
    Brain Res Bull; 2005 May; 65(5):405-13. PubMed ID: 15833595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-synuclein enhances dopamine D2 receptor signaling.
    Kim SJ; Kim SY; Na YS; Lee HJ; Chung KC; Baik JH
    Brain Res; 2006 Dec; 1124(1):5-9. PubMed ID: 17087919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates.
    Purisai MG; McCormack AL; Langston WJ; Johnston LC; Di Monte DA
    Neurobiol Dis; 2005 Dec; 20(3):898-906. PubMed ID: 16006134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice.
    Robertson DC; Schmidt O; Ninkina N; Jones PA; Sharkey J; Buchman VL
    J Neurochem; 2004 Jun; 89(5):1126-36. PubMed ID: 15147505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.
    Chu Y; Dodiya H; Aebischer P; Olanow CW; Kordower JH
    Neurobiol Dis; 2009 Sep; 35(3):385-98. PubMed ID: 19505575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship among alpha-synuclein accumulation, dopamine synthesis, and neurodegeneration in Parkinson disease substantia nigra.
    Mori F; Nishie M; Kakita A; Yoshimoto M; Takahashi H; Wakabayashi K
    J Neuropathol Exp Neurol; 2006 Aug; 65(8):808-15. PubMed ID: 16896314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formation of dopamine-mediated alpha-synuclein-soluble oligomers requires methionine oxidation.
    Leong SL; Pham CL; Galatis D; Fodero-Tavoletti MT; Perez K; Hill AF; Masters CL; Ali FE; Barnham KJ; Cappai R
    Free Radic Biol Med; 2009 May; 46(10):1328-37. PubMed ID: 19248830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.